The study, published in Genes & Immunity, examined transcriptional patterns linked to immune-cell infiltration in three publicly available breast cancer datasets. Rather than relying only on microscopic estimates of immune-cell abundance, the researchers analyzed gene-expression signatures that can indicate which immune populations are present in a tumor and whether those cells appear functionally activated. This approach, often called transcriptomic deconvolution, uses characteristic sets of genes to estimate the relative contribution of different cell types within a mixed tissue sample. The analysis revealed a consistent association between mast-cell states and clinical outcomes among patients with hormone receptor-positive, HER2-negative breast cancer.

Hormone receptor-positive, HER2-negative disease represents a large proportion of breast cancer cases. These tumors generally depend on estrogen or progesterone signaling for growth but lack overexpression of the HER2 protein, which can drive aggressive tumor behavior and can be targeted with specific drugs. Endocrine therapies are central to treatment, yet resistance and relapse remain significant clinical challenges. Unlike triple-negative and HER2-positive breast cancers, where higher levels of tumor-infiltrating lymphocytes often correlate with better survival, lymphocyte abundance has not shown the same predictive value in hormone receptor-positive, HER2-negative tumors. The new findings suggest that the immune biology of these cancers may need to be assessed through a wider lens.

The most striking observation involved the distinction between resting and activated mast cells. Greater infiltration by resting mast cells was repeatedly associated with improved survival indicators, whereas activated mast-cell signatures did not show the same favorable relationship. Mast cells are long-lived immune cells that reside in tissues and can release a broad range of biologically active substances, including histamine, proteases, cytokines and growth factors. Depending on their surroundings, these mediators can influence blood-vessel formation, tissue remodeling, inflammation and interactions between immune cells and cancer cells. Their effects are therefore highly context-dependent and cannot be classified as uniformly protective or harmful.

In the analyzed tumors, the presence of resting mast cells was inversely related to infiltration by other immune cells and to gene-expression markers associated with cancer-cell proliferation. At the same time, it correlated positively with stromal richness, meaning a greater contribution from the non-malignant structural compartment of the tumor. The stroma includes fibroblasts, connective-tissue proteins, small blood vessels and signaling molecules that provide both physical support and biochemical instructions to nearby cells. These relationships suggest that resting mast cells may be markers of a more organized or less aggressively inflamed tumor environment rather than direct agents of tumor destruction.

The finding is important because it shifts attention away from a simple question—how many immune cells are inside a tumor?—toward a more precise one: which immune cells are present, what state are they in, and how are they communicating with neighboring tissues? A tumor with abundant immune infiltration is not necessarily biologically favorable if those cells are suppressed, misdirected or associated with chronic inflammation. Conversely, a tumor with fewer conventional lymphocytes may still contain cellular networks that influence disease behavior through stromal organization and tissue repair pathways. Mast-cell activity could therefore complement established biomarkers rather than replace them.

One possible explanation is that interactions between resting mast cells and fibroblasts help shape a tumor microenvironment that is less supportive of rapid cancer-cell expansion. Fibroblasts can produce extracellular-matrix components and signaling factors that affect tumor stiffness, drug penetration, cell migration and immune access. Mast cells can influence fibroblast behavior through soluble mediators and direct cellular interactions. The balance between these populations may determine whether the stroma acts as a barrier, a scaffold for invasion or a relatively stable tissue compartment. However, the current study did not directly demonstrate such a mechanism. The proposed connection remains a biologically plausible hypothesis that will require laboratory and clinical investigation.

The results also carry potential implications for treatment sensitivity. Endocrine therapy, chemotherapy and emerging immune-based strategies can be affected by the physical and molecular properties of the tumor microenvironment. Dense or altered stroma may limit drug distribution, while inflammatory signaling can either stimulate immune attack or promote resistance. If mast-cell transcriptional states reliably identify tumors with distinct stromal and proliferative features, they could eventually contribute to risk stratification or help define groups for prospective clinical trials. Developing such applications would require standardized assays, validation in independent patient cohorts and proof that the signatures provide information beyond established clinical and genomic predictors.

The investigators emphasize that their conclusions are based on retrospective analyses of existing transcriptomic data. Gene-expression signatures estimate cellular abundance and functional state, but they do not provide the same direct evidence as tissue imaging, functional experiments or prospective treatment studies. An association between resting mast cells and longer survival does not prove that these cells cause better outcomes; they may instead be indicators of another protective feature of the tumor microenvironment. Even so, the consistency of the observation across three datasets strengthens the case for further research. By highlighting mast-cell state and stromal biology in hormone receptor-positive, HER2-negative breast cancer, the study opens a new avenue for understanding why apparently similar tumors can behave so differently—and why the next generation of personalized cancer care may need to profile not only malignant cells, but the entire ecosystem in which they survive.

Subject of Research: The association between resting mast-cell transcriptional signatures, tumor microenvironment features and clinical outcomes in hormone receptor-positive, HER2-negative breast cancer.

Article Title: A transcriptional signature of resting mast cells is associated with improved disease outcome in HR⁺HER2^– breast cancer.

Article References: Kirchmair, A., Galassi, C., García-Torralba, E. et al. “A transcriptional signature of resting mast cells is associated with improved disease outcome in HR⁺HER2^– breast cancer.” Genes & Immunity (2026). https://doi.org/10.1038/s41435-026-00409-y

Image Credits: AI Generated

DOI: 10.1038/s41435-026-00409-y

Keywords: breast cancer, hormone receptor-positive breast cancer, HER2-negative breast cancer, mast cells, tumor microenvironment, transcriptomics, fibroblasts, cancer prognosis, immune infiltration, personalized oncology

At baseline, tumors from patients who subsequently exhibited a durable clinical benefit demonstrated a significantly higher infiltration of T cells, as determined through transcriptomic deconvolution methodologies, compared to those without DCB. Notably, despite no marked differences in total CD8+ T cell infiltration across various detection platforms, tumors in the DCB group harbored a higher frequency of CD8+PD1+ T cells. This observation underscores the potential importance of an exhausted or activated CD8+ T cell subset as a biomarker predictive of immunotherapy response, highlighting the nuanced roles of T cell functional states within the tumor milieu.

The research team further explored immune-tumor interactions by evaluating expression levels of major histocompatibility complex class I molecules. Immunohistochemical analysis revealed a trend favoring elevated HLA-I protein expression in tumors from the responsive cohort, with RNA expression data showing particularly robust differences in HLA-B alleles. These findings suggest that enhanced antigen presentation capacity via MHC-I pathways could be instrumental in enabling effective recognition and cytotoxic responses from CD8+ T cells. Interestingly, tumors with lower HLA-I levels corresponded to a relative increase in natural killer (NK) cells, although absolute NK infiltration did not differ significantly, hinting at compensatory innate immune dynamics in less responsive tumors.

MHC class II-dependent immunity emerged as a pivotal correlate of therapeutic outcome. The study reports significantly higher baseline protein levels of pan-HLA-II, along with increased transcription of multiple MHC-II genes, in tumors from patients who achieved DCB. This enhanced MHC-II expression aligns with a pronounced upregulation of T helper 1 (TH1) cell-associated markers such as TBX21 and CXCR3, and importantly, the key immunomodulatory cytokine IFNG (interferon gamma). Such a cytokine milieu potentially fosters an immune-permissive microenvironment, further complemented by elevated PD-L1 expression both transcriptionally and at the protein level, indicative of active immune checkpoint engagement.

A strong functional cytotoxic immune signature was corroborated by elevated levels of granzyme family members (GZMA, GZMB, and GZMK) in tumor secretomes and RNA sequencing datasets, pointing to the presence of active cytolytic effector cells capable of targeting malignancies effectively. These observations underscore the complex interplay between antigen presentation, cytokine signaling, and cytotoxic effector function as cornerstones of an effective anti-tumor immune response.

Beyond CD8+ cytotoxic T lymphocytes, the study highlights the enrichment of follicular helper T (TFH) cells within tumors of responders. Markers characteristic of TFH biology, including BCL6, CXCR5, and CXCL13, were significantly elevated, suggesting that these specialized CD4+ T cells may facilitate effective B cell-mediated immunity. Supporting this notion, B cell transcriptional signatures, increased CD20 protein expression, and markers of plasma cell differentiation such as CD38 and PRDM1 were also augmented in tumors exhibiting DCB. This coordinated activation of both T and B cell compartments may represent a critical axis of tumor immune surveillance and elimination.

Intriguingly, the data reveals a positive correlation between CD8+ T cell and CD20+ B cell infiltrates, and the presence of tertiary lymphoid structures (TLSs) within tumors further coincided with elevated CD8+ T cell infiltration. While TLS detection demonstrated high specificity for DCB, its sensitivity remained limited, indicating that other immune features are also critical to therapeutic success. These findings strengthen the idea that robust and spatially organized adaptive immune responses within the tumor microenvironment are beneficial for clinical outcomes.

Longitudinal analyses following treatment initiation revealed a rapid intensification of these pre-existing immune features in patients with DCB. Three weeks post-therapy, these tumors displayed increases in helper T cells, plasma cell markers, and CD8+ T cell infiltration across multiple analytical platforms. Enhanced activation was evidenced by higher frequencies of HLA-DR+ and CD39+ CD8+ T cells, accompanied by augmented IFNγ production and granzyme expression within the tumor bed, establishing a dynamic immune amplification process post immunotherapy.

Histopathological examination at this early treatment timepoint revealed a significant reduction in cancer cell content paired with increased necrosis and stromal deposition in responsive tumors. Such tissue remodeling may reflect efficient immune-mediated tumor eradication, further emphasizing the biological impact of checkpoint blockade in these patients.

In a holistic view, the study illustrates that successful combination immunotherapy hinges upon an existing, albeit latent, adaptive immune response characterized by robust MHC class I and II antigen presentation, coordinated TH1 and TFH CD4+ T cell responses, active cytotoxic T lymphocytes, and a thriving B cell compartment. The observed rapid reactivation and expansion of these immune constituents early after treatment initiation delineate a mechanistic framework for durable clinical benefit.

To elucidate mechanisms underpinning treatment resistance, the authors also probed the immunosuppressive constituents within the tumor microenvironment. Notably, regulatory T cells (Tregs) and M2-like macrophages were found to be abundant in tumors from patients who responded to therapy, suggesting a nuanced role for these populations in modulating immune responses. These findings challenge classical models of unidirectional immunosuppression by Tregs and macrophages, hinting that their presence may relate to robust immune regulation necessary for effective antitumor immunity.

Collectively, this comprehensive profiling underscores the imperative of considering both immunostimulatory and immunoregulatory elements within the tumor microenvironment when designing and evaluating immunotherapeutic strategies. Furthermore, it advocates for personalized assessment of immune contexture to predict and enhance patient responses in the era of precision oncology.

Given the promising associations uncovered between immune signatures and clinical efficacy, future investigations may refine biomarkers to stratify patients for tailored checkpoint blockade regimens. In addition, these insights pave the way for innovative combination approaches incorporating agents targeting immune suppressor subsets to overcome resistance and optimize therapeutic benefits.

This landmark study advances our understanding of the complex immunological underpinnings of anti-CTLA4 and anti-PD1 combination therapy, offering a roadmap to harness and amplify endogenous adaptive immunity for transformative cancer treatment.

Subject of Research: Immune features associated with efficacy of combined intratumoural anti-CTLA4 and intravenous anti-PD1 immunotherapy in cancer.

Article Title: Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Article References:
Tselikas, L., Susini, S., Texier, M. et al. Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1. Nature (2026). https://doi.org/10.1038/s41586-026-10341-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10341-w